Drugs / 11C-MK-3168
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04404712 | Sep 2020 → Jun 2021 | alcohol-related disorders, post-traumatic stress disorder, psychotic disorder | Yale University | Terminated | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02169973 | Feb → Jul 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 11C-MK-3168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02169973 ↗ |
| Known as | MK-3168 C-11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2386558 ↗ |
| Modality | Diagnostic / imaging agent | “Positron Emission Tomography Ligand 11C-MK-3168” NCT02169973 ↗ |
| Route | Intravenous | “185 to 370 megabecquerel (MBq) intravenously (into a vein)” NCT02169973 ↗ |